VITVO at Therapeutic nanoproducts: from biology to innovative technology conference organized by Istituto Superiore di Sanità and AICC on June, 19-20 2019
Rigenerand is proud to present VITVO at Therapeutic nanoproducts: from biology to innovative technology conference organized by Istituto Superiore di Sanità and AICC on June, 19-20 2019.
Dr. Olivia Candini, R&D Manager of 3D-Culture Technologies division, will have a talk about VITVO applications and potentials on June 20th.
For more infos about the event:
https://www.aicc.website/eventi-aicc/therapeutic-nanoproducts-from-biology-to-innovative-technology/
Rigenerand VITVO published on Scientific Reports
Medolla – 10 May 2019. Scientific Reports just published the Rigenerand new technology to culture cells in 3D for pre-clinical studies from gene therapy to immunotherapy. “We are proud to present this novel and breakthrough technology on this prestigious academic Journal” says Massimo Dominici MD, Rigenerand founder and scientific coordinator, “VITVO is contributing to fill gaps between in silico hypothesis/in vitro results and in vivo settings also significantly impacting on the 3R rules”. Olivia Candini PhD, the first author of the manuscript and head of Cell and Tissue Engineering R&D, underlines that “VITVO is having a relevant impact in 3D-cultures due to novel features that will empower the most advanced research in cancer additionally boosting other approaches in drug developments”. “Starting from a start-up perspective, Rigenerand is now positioning as leader in the 3D-cultures with published peer-reviewed data that solidly support the proposed technology as tool that allows unprecedented in vitro investigations“ closes Giorgio Mari, Rigenerand CEO. Further Readings Candini O, Grisendi G, Foppiani E, Brogli M, Aramini B, Masciale V, Spano C, Petrachi T, Veronesi E, Conte P, Mari G & Dominici M. A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology. Sci Rep. 2019; 9:7154. Available if you like to read it
Rigenerand scientific founder Massimo Dominici recognized as one of the Global Cell and Gene Therapy Opinion Leaders
Medolla (Modena) - 03 May 2019. The Medicine Maker a global publication in cell and gene therapy, lists the world’s top 100 thought leaders and opinion shapers who have carried out life-changing work in the biopharmaceutical industry. This year, The Medicine Maker’s Power List 2019 has included Massimo Dominici MD, Rigenerand Scientific Founder and Professor of Oncology at the University of Modena & Reggio Emilia, in the category Champions of Change. “It is really a honor to be recognized in the list amongst such company of global KOL and Nobel Prize winners,” says Dr. Dominici also Past President of the International Society of Cell and Gene Therapy (ISCT) and current Chair of the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapy. The annual Medicine Maker Power List recognizes the most inspiring and influential people across the entire global life sciences sector – from entrepreneurs and CEOs, to industry experts, researchers, and regulators. Reaching a diverse, broad audience around the world, The Medicine Maker is a tier-one publication that celebrates the people, processes and vision that bring new drugs and biologics to the public. The extensive Power List was compiled based on the votes of Medicine Maker readers as well as the input of an expert judging panel made up of influencers in the biopharmaceutical industry.
Related Links
- https://themedicinemaker.com/power-list/2019#champions%20of%20change
- https://www.celltherapysociety.org/news/448122/3-ISCT-Leaders-Recognized-as-Global-Cell-and-Gene-Therapy-Influencers.htm
- https://finance.yahoo.com/news/3-isct-leaders-recognized-global-090000112.html
- https://eprnews.com/3-isct-leaders-recognized-as-global-cell-and-gene-therapy-influencers-403804